Publications
Publications
Show Results For
- All HBS Web
(945)
- Faculty Publications (249)
- 2024
- Working Paper
Health, Human Capital Development and the Longevity of Japanese Elites Since 710
By: Tom Nicholas and Hiroshi Shimizu
We examine the lifespan of over 40,000 elites in Japan born between 710 and 1912, including samurai warriors, feudal lords, business, political, cultural, and religious leaders at the apex of the social hierarchy. Japanese elites experienced increases in lifespan about... View Details
- June 2024
- Article
The Monitoring Role of Social Media
By: Jonas Heese and Joseph Pacelli
In this study, we examine whether social media activity can reduce corporate misconduct. We use the staggered introduction of 3G mobile broadband access across the United States to identify exogenous increases in social media activity and test whether access to 3G... View Details
- April 29, 2024
- Editorial
Stemming the Ripple Effect of Untreated Mental Illness: A Prescription for Change: Reimagining U.S. Healthcare
By: Lidia Moura and Susanna Gallani
- April 2024 (Revised July 2024)
- Case
Market Dynamics and Moral Dilemmas: Novo Nordisk’s Weight-Loss Drugs
By: Joseph L. Badaracco, Tom Quinn and John Schultz
Danish pharmaceutical company Novo Nordisk was owned by a charitable foundation, and since its founding in the 1920s had focused on producing insulin to treat diabetes. In 2017, however, it released Ozempic, a diabetes treatment with the revolutionary side effect of... View Details
Keywords: Cost vs Benefits; Decisions; Judgments; Values and Beliefs; Global Strategy; Health Care and Treatment; Patents; Growth and Development Strategy; Growth Management; Product Positioning; Supply and Industry; Supply Chain; Corporate Social Responsibility and Impact; Mission and Purpose; Philanthropy and Charitable Giving; Opportunities; Social Issues; Equality and Inequality; Pharmaceutical Industry; Health Industry; Denmark; United States; Europe; China; India; Middle East; North Africa
- 2024
- Working Paper
The Effects of Medical Debt Relief: Evidence from Two Randomized Experiments
By: Raymond Kluender, Neale Mahoney, Francis Wong and Wesley Yin
Two in five Americans have medical debt, nearly half of whom owe at least $2,500. Concerned by this burden, governments and private donors have undertaken large, high-profile efforts to relieve medical debt. We partnered with RIP Medical Debt to conduct two randomized... View Details
- 2023
- Working Paper
An Experimental Design for Anytime-Valid Causal Inference on Multi-Armed Bandits
By: Biyonka Liang and Iavor I. Bojinov
Typically, multi-armed bandit (MAB) experiments are analyzed at the end of the study and thus require the analyst to specify a fixed sample size in advance. However, in many online learning applications, it is advantageous to continuously produce inference on the... View Details
- 2023
- Working Paper
Design-Based Inference for Multi-arm Bandits
By: Dae Woong Ham, Iavor I. Bojinov, Michael Lindon and Martin Tingley
Multi-arm bandits are gaining popularity as they enable real-world sequential decision-making across application areas, including clinical trials, recommender systems, and online decision-making. Consequently, there is an increased desire to use the available... View Details
- 2025
- Working Paper
Exports in Disguise? Trade Rerouting During the U.S.-China Trade War
By: Ebehi Iyoha, Edmund Malesky, Jaya Wen and Sung-Ju Wu
This paper introduces a new measure of tariff evasion through rerouting and applies it to the
2018 U.S.–China trade war, focusing on Vietnam as a transit country. We use transaction-level trade data and define rerouting as the flow of a granular eight-digit Harmonized... View Details
- March 2024
- Article
Medicare Price Negotiation and Pharmaceutical Innovation Following the Inflation Reduction Act
By: Matthew Vogel, Pragya Kakani, Amitabh Chandra and Rena M. Conti
The Inflation Reduction Act (IRA) requires Medicare to negotiate lower prices for some medicines with high Medicare spending. Using historical data from public and proprietary sources to apply the IRA's negotiation criteria retrospectively, we identify all drugs that... View Details
- 2023
- Working Paper
'De Gustibus' and Disputes about Reference Dependence
By: Thomas Graeber, Pol Campos-Mercade, Lorenz Goette, Alexandre Kellogg and Charles Sprenger
Existing tests of reference-dependent preferences assume universal loss aversion. This paper examines the implications of heterogeneity in gain-loss attitudes for such tests. In experiments on labor supply and exchange behavior we measure gain-loss attitudes and then... View Details
- January 2024
- Article
Population Interference in Panel Experiments
By: Kevin Wu Han, Guillaume Basse and Iavor Bojinov
The phenomenon of population interference, where a treatment assigned to one experimental unit affects another experimental unit’s outcome, has received considerable attention in standard randomized experiments. The complications produced by population interference in... View Details
- 2023
- Working Paper
Money, Time, and Grant Design
By: Kyle Myers and Wei Yang Tham
The design of research grants has been hypothesized to be a useful tool for
influencing researchers and their science. We test this by conducting two thought
experiments in a nationally representative survey of academic researchers. First,
we offer participants a... View Details
- December 2023
- Teaching Note
Buurtzorg
By: Ethan Bernstein and Tatiana Sandino
Teaching Note for HBS Case No. 122-101. As co-founders of home nursing company Buurtzorg, Jos de Blok and Gonnie Kronenberg prized both self-management and organizational learning. Buurtzorg’s 10,000 nurses across 950 neighborhood nursing teams in the Netherlands were... View Details
- 2025
- Working Paper
Enhancing Treatment Effect Prediction on Privacy-Protected Data: An Honest Post-Processing Approach
By: Ta-Wei Huang and Eva Ascarza
As firms increasingly rely on customer data for personalization, concerns over privacy and regulatory compliance have grown. Local Differential Privacy (LDP) offers strong individual-level protection by injecting noise into data before collection. While... View Details
- 2023
- Working Paper
Estimating Productivity in the Presence of Spillovers: Firm-Level Evidence from the U.S. Production Network
By: Ebehi Iyoha
This paper examines the extent to which productivity gains are transmitted across U.S. firms through buyer-supplier relationships. Many empirical studies measure firm-to-firm spillovers using firm-level productivity estimates derived from control function approaches.... View Details
- 2023
- Article
Balancing Risk and Reward: An Automated Phased Release Strategy
By: Yufan Li, Jialiang Mao and Iavor Bojinov
Phased releases are a common strategy in the technology industry for gradually releasing new products or updates through a sequence of A/B tests in which the number of treated units gradually grows until full deployment or deprecation. Performing phased releases in a... View Details
- 2024
- Working Paper
The Uneven Impact of Generative AI on Entrepreneurial Performance
By: Nicholas G. Otis, Rowan Clarke, Solène Delecourt, David Holtz and Rembrand Koning
Scalable and low-cost AI assistance has the potential to improve firm decision-making and economic performance. However, running a business involves a myriad of open-ended problems, making it difficult to know whether recent AI advances can help business owners make... View Details
- 2023
- Working Paper
Deglobalization and Entrepreneurial Investment: The Natural Experiment of Brexit
By: Elisa Alvarez-Garrido and Juan Alcácer
We seek to gain insight into the consequences of deglobalization on entrepreneurial investment by
analyzing an instance of economic disintegration: the United Kingdom’s exit from the European Union.
Brexit is not only a unique empirical opportunity, a natural... View Details
- 2023
- Working Paper
Are Hospital Quality Indicators Causal?
By: Amitabh Chandra, Maurice Dalton and Douglas O. Staiger
Hospitals play a key role in patient outcomes and spending, but efforts to improve their quality are hindered because we do not know whether hospital quality indicators are causal or biased. We evaluate the validity of commonly used quality indicators, such as... View Details
- October 2023
- Article
What Does the Inflation Reduction Act Mean for Patients and Physicians?
By: Amitabh Chandra and Benedic Ippolito
The debate around prescription drug measures in the recently passed U.S. Inflation Reduction Act (IRA), which limit some patients’ out-of-pocket costs, has not fully addressed their effect on physicians and patients via their effect on payers. Reducing patients’ costs... View Details